Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 10/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.37 |
| ▸ | CDK2 | P24941 | 9/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187054 | 0.81 | DHFR (0.33) | — | |
| SCHEMBL16884033 | 0.80 | PDE10A (0.31) | CDK2CDK1 | |
| SCHEMBL14236367 | 0.79 | NPC1 (0.33) | CDK5CDK5R1NPC1POLB | |
| SCHEMBL15723693 | 0.79 | CDK1 (0.44) | CDK2CDK1 | |
| SCHEMBL22822733 | 0.79 | HCAR3 (0.30) | CDK2CDK1 | |
| SCHEMBL844838 | 0.76 | PIK3CB (0.38) | CDK1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24334808 | 0.74 | CCNA2 (0.31) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL21087796 | 0.74 | LRRK2 (0.56) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL28235839 | 0.74 | RPS6KA5 (0.38) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL19152607 | 0.74 | CNR2 (0.39) | CDK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDK5 3184/4885CDK5R1 3568/4885CCNA2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.